Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A structural basis for interferon-alpha-receptor interactions.

Jyothi Kumaran1, Lianhu Wei, Lakshmi P Kotra

  • 1Division of Cell and Molecular Biology, Toronto General Research Institute, Toronto, ON M5G 2M1 Canada.

FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|May 23, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a SIN1 Targeting Inhibitor as a Novel Therapeutic Approach for the Treatment of Malignancies.

Molecular cancer therapeutics·2025
Same author

Synthesis and Biological Evaluation of Small Molecule Inhibitors of Immune Cytopenias.

ACS omega·2025
Same author

Acyl-CoA Thioesterase 1 Contributes to Transition of Steatosis to Metabolic-Associated Steatohepatitis.

International journal of hepatology·2024
Same author

Stereoisomers of cannabidiols and their pharmacological activities - A potentially novel direction for cannabinoids.

Bioorganic & medicinal chemistry·2024
Same author

A novel small molecule phagocytosis inhibitor, KB-208, ameliorates ITP in mouse models with similar efficacy as IVIG.

Transfusion·2024
Same author

Signaling by Type I Interferons in Immune Cells: Disease Consequences.

Cancers·2024

Interferon (IFN)-alpha subtypes vary in potency due to receptor binding. Computational models reveal key interactions between IFNs and IFNAR2, explaining differences in binding affinity and species specificity.

Area of Science:

  • Biochemistry
  • Structural Biology
  • Immunology

Background:

  • Interferon (IFN)-alpha subtypes possess varying biological potencies.
  • These differences are attributed to their affinity interactions with IFN receptor subunits, IFNAR1 and IFNAR2.

Purpose of the Study:

  • To computationally model and analyze the binding interfaces between human IFN-alpha subtypes and the human IFNAR2 receptor.
  • To investigate the structural basis for species specificity in IFN-alpha interactions.

Main Methods:

  • Homology modeling of human IFN-alpha1, IFN-alpha8, IFN alfacon-1, and murine IFN-alpha4.
  • Computational docking of IFN models with the extracellular region of human IFNAR2.
  • Generation and docking of an IFNAR1 model with IFN-IFNAR2 complexes.

Related Experiment Videos

Main Results:

  • IFN alfacon-1 showed 9 optimal interactions with IFNAR2, followed by human IFN-alpha2 (8), human IFN-alpha1 (7), and murine IFN-alpha4 (5).
  • Structural analysis identified specific residues contributing to binding affinity and species-specific interactions.
  • Models elucidated the complete extracellular receptor pocket with bound IFN.

Conclusions:

  • Computational modeling provides insights into the molecular mechanisms underlying IFN-alpha subtype potency and receptor binding.
  • Specific residues dictate species specificity, explaining differential interactions with human and murine IFNAR.
  • This study enhances understanding of interferon-receptor interactions for potential therapeutic applications.